Inventor · disambiguated record
Florian Von Der Mülbe
Also filed as: VON DER MUELBE FLORIAN · VON DER MULBE FLORIAN · VON DER MÜLBE FLORIAN
19 granted patents·12 pending applications·732 citations·filing 2003–2024
97Inventor score
Top patents by PatentIndex Score
31 records- 0199US9655955B2Application of mRNA for use as a therapeutic against tumour diseasesCUREVAC AG·Filed 2015·Granted May 23, 2017·42 cites·20 claims
- 0299US9463228B2Application of mRNA for use as a therapeutic against tumour diseasesCUREVAC AG·Filed 2015·Granted Oct 11, 2016·28 cites·20 claims
- 0399US9439956B2Application of mRNA for use as a therapeutic against tumour diseasesCUREVAC AG·Filed 2015·Granted Sep 13, 2016·29 cites·19 claims
- 0499US9433669B2Application of mRNA for use as a therapeutic against tumor diseasesCUREVAC AG·Filed 2015·Granted Sep 6, 2016·29 cites·20 claims
- 0599US9433670B2Application of mRNA for use as a therapeutic against tumour diseasesCUREVAC AG·Filed 2015·Granted Sep 6, 2016·29 cites·20 claims
- 0698US11135312B2Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regionsCUREVAC AG·Filed 2014·Granted Oct 5, 2021·35 cites·16 claims
- 0798US10568972B2Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regionsCUREVAC AG·Filed 2016·Granted Feb 25, 2020·35 cites·23 claims
- 0898US9155788B2Application of mRNA for use as a therapeutic against tumour diseasesCUREVAC GMBH·Filed 2014·Granted Oct 13, 2015·64 cites·20 claims
- 0998US8217016B2Application of mRNA for use as a therapeutic agent for tumorous diseasesHOERR INGMAR·Filed 2004·Granted Jul 10, 2012·195 cites·27 claims
- 1097US11661634B2Method for producing RNACUREVAC MFG GMBH·Filed 2022·Granted May 30, 2023·7 cites·30 claims
- 1197US11446250B2Lyophilization of RNACUREVAC REAL ESTATE GMBH·Filed 2020·Granted Sep 20, 2022·14 cites·30 claims
- 1297US11369691B2Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regionsCUREVAC AG·Filed 2016·Granted Jun 28, 2022·11 cites·19 claims
- 1397US11268157B2Method for producing RNACUREVAC REAL ESTATE GMBH·Filed 2020·Granted Mar 8, 2022·29 cites·18 claims
- 1497US10780054B2Lyophilization of RNACUREVAC REAL ESTATE GMBH·Filed 2016·Granted Sep 22, 2020·44 cites·17 claims
- 1597US10711315B2Method for producing RNACUREVAC REAL ESTATE GMBH·Filed 2018·Granted Jul 14, 2020·28 cites·16 claims
- 1696US11491112B2Lyophilization of RNACUREVAC MFG GMBH·Filed 2021·Granted Nov 8, 2022·12 cites·36 claims
- 1796US10017826B2Method for producing RNACUREVAC AG·Filed 2016·Granted Jul 10, 2018·29 cites·34 claims
- 1895US10188748B2Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regionsVON DER MUELBE FLORIAN·Filed 2003·Granted Jan 29, 2019·72 cites·32 claims
- 1986US2025099388A1Lyophilization of rnaCUREVAC MFG GMBH·Filed 2024·Application pending·0 cites
- 2081US12194148B2Lyophilization of RNACUREVAC MFG GMBH·Filed 2022·Granted Jan 14, 2025·0 cites·20 claims
- 2179US2022154253A1Method for producing rnaCUREVAC REAL ESTATE GMBH·Filed 2022·Application pending·0 cites
- 2270US2019134222A1PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONSCUREVAC AG·Filed 2018·Application pending·0 cites
- 2367US2023181765A2PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONSCureVac SE·Filed 2016·Application pending·0 cites
- 2466US2017211068A1Immunostimulation by chemically modified rnaCUREVAC AG·Filed 2017·Application pending·0 cites
- 2564US2016361438A1PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONSCUREVAC AG·Filed 2016·Application pending·0 cites
- 2661US2011269950A1PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONSCUREVAC GMBH·Filed 2011·Application pending·0 cites
- 2759US2005250723A1Immunostimulation by chemically modified RNAHOERR INGMAR·Filed 2004·Application pending·0 cites
- 2858US2011311472A1Application of mrna for use as a therapeutic against tumour diseasesHOERR INGMAR·Filed 2011·Application pending·0 cites
- 2958US2011077287A1Pharmaceutical composition containing a stabilised mrna optimised for translation in its coding regionsCUREVAC GMBH·Filed 2010·Application pending·0 cites
- 3058US2010239608A1PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONSCUREVAC GMBH·Filed 2010·Application pending·0 cites
- 3153US2006188490A1Transfection of blood cells with mRNA for immune stimulation and gene therapyHOERR INGMAR·Filed 2006·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Florian Von Der Mülbe files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →